Background: Epidermal growth factor (EGF) in saliva is cytoprotective against injuries and contributes to the maintenance of the integrity of the gastrointestinal mucosa. Low salivary EGF levels have been observed in patients with various forms of oral mucosal disease. Objective: Our aim wasto determine whether salivary EGF is low in patients with recurrent aphthous stomatitis (RAS) or those with Behçet’s disease (BD) when compared with healthy controls. Methods: The study population consisted of 33 BD and 16 RAS patients and 60 healthy controls. Measurement of EGF concentration in human saliva was performed with an enzyme-linked immunosorbent assay using an antibody-coated solid phase. Results: The mean salivary EGF levels (±SD) of active (with oral ulceration) and inactive stages (absence of oral ulceration) of BD (1,939.7 ± 1,561.5 and 2,305.7 ± 1,481.6 pg/ml, respectively) and RAS patients (1,650.5 ± 704.7 and 1,069.9 ± 539.2 pg/ml, respectively) were both lower than those of the healthy controls (2,758.7 ± 1,657.9 pg/ml) (p < 0.05 for each). Conclusions: BD and RAS patients have reduced salivary EGF levels even in the absence of oral ulcerations. EGF could be involved in the pathogenesis of BD and RAS by disturbing the mucosal integrity that may result in a susceptibility to the development of oral ulcers in these diseases.

Keywords:
Behçet’s disease, Oral ulceration, Etiology, Salivary epidermal growth factor
1.
Scully C, Porter S: Recurrent aphthous stomatitis: current concepts of etiology, pathogenesis and management. J Oral Pathol Med 1989;18:21–27.
2.
Evereklioglu C: Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297–350.
3.
Field EA, Allan RB: Review article: oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther 2003;18:949–962.
4.
Lehner T: Autoimmunity in oral diseases, with special reference to recurrent oral ulceration. Proc R Soc Med 1968;61:515–524.
5.
International Study Group for Behçet’s Disease: criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
6.
Orem A, Cimşit G, Değer O, Vanizor B, Karahan SC: Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet’s disease. Dermatology 1999;198:243–246.
7.
Alpsoy E, Elpek GO, Yilmaz F, Ciftcioglu MA, Akman A, Uzun S, Karakuzu A: Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behçet’s disease. Dermatology 2005;210:31–35.
8.
Gül U, Gönül M: Oral and genital pathergy in Behçet’s disease. Dermatology 2007;215:80–81.
9.
Buno IJ, Huff JC, Weston WL, Cook DT, Brice SL: Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol 1998;134:827–831.
10.
Yalcin B, Arda N, Tezel GG, Erman M, Alli N: Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behçet’s disease. Anal Quant Cytol Histol 2006;28:303–306.
11.
Brozovic S, Vucicevic-Boras V, Mravak-Stipetic M, Jukic S, Kleinheinz J, Lukac J: Salivary levels of vascular endothelial growth factor (VEGF) in recurrent aphthous ulceration. J Oral Pathol Med 2002;31:106–108.
12.
Wu-Wang CY, Patel M, Feng J, Milles M, Wang SL: Decreased levels of salivary prostaglandin E2 and epidermal growth factor in recurrent aphthous stomatitis. Arch Oral Biol 1995;40:1093–1098.
13.
Ino M, Ushiro K, Ino C, Yamashita T, Kumazawa T: Kinetics of epidermal growth factor in saliva. Acta Otolaryngol 1993;5:126–130.
14.
Rao RK, Thomas DW, Pepperl S, Porreca F: Salivary epidermal growth factor plays a role in protection of ileal mucosal integrity. Dig Dis Sci 1997;42:2175–2181.
15.
Ma L, Wang WP, Chow JY, Yuen ST, Cho CH: Reduction of EGF is associated with the delay of ulcer healing by cigarette smoking. Am J Physiol Gastrointest Liver Physiol 2000;278:G10–G17.
16.
Noguchi S, Ohba Y, Oka T: Effect of salivary epidermal growth factor on wound healing of tongues in mice. Am J Physiol 1991;260:E620–E625.
17.
Wright NA, Pike C, Elia G: Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 1990;343:82–85.
18.
Konturek PC, Brzozowski T, Konturek SJ, Ernst H, Drozdowicz D, Pajdo R, Hahn EG: Expression of epidermal growth factor and transforming growth factor α during ulcer healing: time sequence study. Scand J Gastroenterol 1997;32:6–15.
19.
Gray MR, Donnelly RJ, Kingsnorth AN: Role of salivary epidermal growth factor in the pathogenesis of Barrett’s columnar lined oesophagus. Br J Surg 1991;78:1461–1466.
20.
Rourk RM, Namiot Z, Sarosiek J, Yu Z, McCallum RW: Impairment of salivary epidermal growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis. Am J Gastroenterol 1994;89:237–244.
21.
Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST: The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 2000;89:2258–2265.
22.
Kelly SM, Crampton J, Hunter JO: Salivary epidermal growth factor deficiency in rheumatoid disease: influence of sicca syndrome. Gut 1989;30:A1485.
23.
Aybay C, Karakus R, Yucel A: Characterization of human epidermal growth factor in human serum and urine under native conditions. Cytokine 2006;35:36–43.
24.
Girdler NM, McGurk M, Aqual S, Prince M: The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration: a Phase I clinical trial. Am J Clin Oncol 1995;18:403–406.
25.
Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P: Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992;18:604–606.
26.
Tsai JC, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDEGF-BB, and bEGF. J Neurosurg 1995;82:864–873.
27.
Ohshima M, Sato M, Ishikawa M, Maeno M, Otsuka K: Physiologic levels of epidermal growth factor in saliva stimulate cell migration of an oral epithelial cell line, HO-1-N-1. Eur J Oral Sci 2002;110:130–136.
28.
Friedkin M, Legg A, Rozengurt E: Antitubulin agents enhance the stimulation of DNA synthesis by polypeptide growth factors in 3T3 mouse fibroblasts. Proc Natl Acad Sci USA 1979;76:3909–3912.
29.
Otto AM, Ulrich MO, Jimenez de Asua L: Colchicine enhances the effect of growth factors on the initiation of DNA synthesis in sparse and confluent Swiss 3T3 cells. Cell Biol Int Rep 1981;5:717–724.
30.
Brown KD, Friedkin M, Rozengurt E: Colchicine inhibits epidermal growth factor degradation in 3T3 cells. Proc Natl Acad Sci USA 1980;77:480–484.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.